pan CEA Antibody (161): sc-73455

Pan CEA Antibody (161) is a mouse monoclonal IgG1 antibody that detects carcinoembryonic antigen (CEA) in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Anti-CEA antibody (161) is particularly valuable in clinical diagnostics as CEA serves as a crucial tumor marker, primarily associated with colorectal cancer, but also relevant in other malignancies. CEA (161) monoclonal antibody recognizes a protein located on the cell surface and plays a significant role in cell adhesion, which is vital for maintaining tissue architecture and facilitating communication between cells. This function is essential not only for normal cellular processes but also in the context of cancer, where altered adhesion properties can contribute to tumor progression and metastasis. The human CEACAM proteins, including CEA, are encoded by genes clustered on chromosome 19, and their expression levels can provide insights into tumor behavior and patient prognosis. CEA (161) antibody enables researchers and clinicians to gain a deeper understanding of CEA′s role in cancer biology, aiding in the development of targeted therapies and improving patient management strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

pan CEA Antibody (161) References:

1. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.  |  Ohta, K., et al. 2002. Anticancer Res. 22: 2597-606. PMID: 12529970
2. CEA family syndrome. Abnormal carcinoembryonic antigen (CEA) levels in asymptomatic retinoblastoma family members.  |  Felberg, NT., et al. 1976. Cancer. 37: 1397-402. PMID: 1260660
3. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients.  |  Mujagić, Z., et al. 2004. Med Arh. 58: 23-6. PMID: 15017899
4. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important.  |  Verberne, CJ., et al. 2013. Ann Surg Oncol. 20: 457-63. PMID: 22948771
5. Serum carcinoembryonic antigen (CEA) in patients with chronic inflammatory bowel disease.  |  Turner, MD., et al. 1973. Digestion. 9: 116-23. PMID: 4772021
6. Carcinoembryonic antigen (CEA) in patients with carcinoma of the digestive tract.  |  Holyoke, D., et al. 1972. Ann Surg. 176: 559-64. PMID: 5077412
7. Plasma carcinoembryonic antigen (CEA) as an indicator for radical or palliative radiotherapy in patients with rectal cancer.  |  Arnott, SJ. 1983. Cancer Detect Prev. 6: 155-9. PMID: 6192917
8. Current status of carcinoembryonic antigen (CEA) and CEA-S assays in the evaluation of neoplasm of the gastrointestinal tract.  |  Nakamura, RM., et al. 1978. Ann Clin Lab Sci. 8: 4-10. PMID: 623429
9. Radioimmunological characterization of carcinoembryonic antigen (CEA) preparations.  |  Zotter, S., et al. 1982. Exp Pathol. 21: 10-20. PMID: 7075716
10. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients.  |  Choi, JS. and Min, JS. 1997. Yonsei Med J. 38: 1-7. PMID: 9100477

The preferred CEACAM5 antibody is CEACAM5 Antibody (CI-P83-1): sc-23928.